Incyte Corporation (NASDAQ:INCY) is one of the relatively cheap S&P 500 stocks Jim Cramer talked about. Cramer mentioned that it is the healthcare stock that “stands out” to him. He stated: “What else? Now, we know healthcare has been mostly a wasteland this year, which is why only four stocks in the group passed the screen. Among those four, the one that stands out to me is Incyte, a biopharma company with nine approved products, mostly in oncology and dermatology, plus a robust pipeline, which is why th ...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). ...

Core Insights - Incyte Corporation is a biopharmaceutical company focused on oncology and serious diseases, competing with major pharmaceutical firms [1] - RBC Capital adjusted its rating for Incyte to "Sector Perform" with a price target increase from $72 to $81, reflecting a more optimistic outlook [2] - The appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer aims to strengthen Incyte's leadership team [3] Stock Performance - The current stock price of Incyte (INCY) is $84.49, with a slight decrease of $0.05 or approximately -0.06% [4] - Over the past year, INCY has seen a high of $87.99 and a low of $53.56, indicating volatility [4] - Incyte's market capitalization is approximately $16.5 billion, with a trading volume of 58,964 shares today [5]

Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes treatments in oncology, inflammation, and autoimmune diseases. Valued at a market cap of $16.5 billion, the company’s portfolio includes drugs such as Jakafi, Monjuvi, Pemazyre, and Opzelura. Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and Incyte fits the label perfectly, with its market cap exceeding this threshold, underscoring its s ...

Core Viewpoint - Incyte (INCY) has received FDA approval for the label expansion of Opzelura (ruxolitinib) cream, now indicated for the treatment of mild to moderate atopic dermatitis in children aged two years and older [1][10]. Group 1: Product Approval and Efficacy - Opzelura is the first topical JAK inhibitor approved in the U.S. for pediatric atopic dermatitis [2]. - The FDA's approval was based on positive results from the phase III TRuE-AD3 study, which demonstrated the safety and efficacy of Opzelura in children aged 2 to less than 12 years [3]. - The study met its primary endpoint, showing significantly more patients treated with Opzelura achieved treatment success compared to those on a vehicle control [4]. - A secondary endpoint was also met, with patients showing at least a 75% improvement in the Eczema Area and Severity Index at week 8 [4]. - The safety profile of Opzelura was consistent with previous data, with no new safety signals observed [5]. Group 2: Sales Performance - Sales of Opzelura reached $283.2 million in the first half of 2025, reflecting a 37% year-over-year increase [5][10]. - The recent label expansion is expected to further boost sales of Opzelura [5]. Group 3: Company Strategy and Diversification - Incyte is focusing on diversifying its revenue base, as it remains heavily dependent on its lead drug, Jakafi, for top-line growth [7][11]. - Jakafi is a JAK1/JAK2 inhibitor approved for multiple indications, including polycythemia vera and myelofibrosis [8]. - Incyte has also entered a global collaboration with Qiagen to develop a diagnostic panel for myeloproliferative neoplasms, which could support its pipeline of investigational treatments [15][16]. Group 4: Market Performance - Year-to-date, Incyte's shares have increased by 24.5%, outperforming the industry growth of 6% [13].

The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the company said on Thursday. ...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis. ...

Group 1: AI Investment Opportunity - Artificial intelligence is considered the greatest investment opportunity of our lifetime, with a strong emphasis on the urgency to invest now [1] - Wall Street is investing hundreds of billions into AI, but there is a critical question regarding the energy supply needed to support this technology [2] - AI data centers consume massive amounts of energy, comparable to the energy needs of a small city, leading to concerns about power grid strain and rising electricity prices [2] Group 2: Company Overview - A specific company, largely overlooked by AI investors, is positioned to benefit from the increasing demand for energy due to AI, owning critical energy infrastructure assets [3][6] - This company is involved in nuclear energy infrastructure and is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors [7] - The company is debt-free and has a significant cash reserve, amounting to nearly one-third of its market cap, which positions it favorably compared to other energy firms [8] Group 3: Market Position and Growth Potential - The company plays a pivotal role in U.S. LNG exportation, which is expected to grow under the current administration's energy policies [7] - It also holds a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines in the AI sector [9] - The company is trading at less than 7 times earnings, indicating it is undervalued compared to its potential in the AI and energy markets [10] Group 4: Future Trends and Talent Pool - The future of industries is being reshaped by AI, which is seen as a major disruptor, and companies that adapt will thrive [11] - There is a growing influx of talent into the AI sector, ensuring continuous innovation and advancements [12] - The combination of AI infrastructure, onshoring trends, and a focus on nuclear energy positions this company uniquely for future growth [14]

Core Insights - Incyte (INCY) announced new 24-week interim data from the STOP-HS program for its pipeline candidate, povorcitinib, in adult patients with moderate to severe hidradenitis suppurativa (HS) [1][7] - The data will be presented at the EADV 2025 Congress, supporting planned regulatory submissions in Europe and the United States in 2025 and early 2026, respectively [2][4] Pipeline and Clinical Data - Povorcitinib is an oral small-molecule JAK1 selective inhibitor targeting HS, a chronic inflammatory skin disease characterized by painful nodules and abscesses [2] - The STOP-HS clinical trial program includes two phase III studies, STOP-HS1 and STOP-HS2, evaluating the efficacy and safety of povorcitinib [4] - New data showed that nearly 60% of efficacy-evaluable patients achieved Hidradenitis Suppurativa Clinical Response (HiSCR)50 at week 24 [5][7] - Patients treated with povorcitinib also reported significant improvements in skin pain, with 62-70% achieving mild or no pain at week 24 [8] Safety Profile - The overall safety profile of povorcitinib remained consistent, with both doses well tolerated across the trials [10] - Treatment-emergent adverse events occurred in 42.4–54.3% of patients transitioning from placebo to povorcitinib at week 12, and in 70.2–78.7% of patients initially randomized to povorcitinib through week 24 [10] Market Performance - Year to date, Incyte's shares have gained 21.5%, outperforming the industry growth of 4.5% [2] - The successful development of povorcitinib is expected to significantly boost Incyte's revenue base, which is currently heavily dependent on its lead drug, Jakafi [12]

Group 1 - Incyte announced new 24-week Phase 3 data from the STOP-HS clinical trial program for Povorcitinib in Hidradenitis Suppurativa at EADV 2025 [1]